173 related articles for article (PubMed ID: 18325729)
1. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety.
Lühe A; Künkele KP; Haiker M; Schad K; Zihlmann C; Bauss F; Suter L; Pfister T
Toxicol In Vitro; 2008 Jun; 22(4):899-909. PubMed ID: 18325729
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
3. Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy.
Bergner R; Siegrist B; Gretz N; Pohlmeyer-Esch G; Kränzlin B
Pharmacol Res; 2015 Sep; 99():16-22. PubMed ID: 25976681
[TBL] [Abstract][Full Text] [Related]
4. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
Fisher JE; Rodan GA; Reszka AA
Endocrinology; 2000 Dec; 141(12):4793-6. PubMed ID: 11108295
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro.
Ziebart T; Pabst A; Klein MO; Kämmerer P; Gauss L; Brüllmann D; Al-Nawas B; Walter C
Clin Oral Investig; 2011 Feb; 15(1):105-11. PubMed ID: 20024592
[TBL] [Abstract][Full Text] [Related]
7. Acute renal effects of intravenous bisphosphonates in the rat.
Pfister T; Atzpodien E; Bohrmann B; Bauss F
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):374-81. PubMed ID: 16364053
[TBL] [Abstract][Full Text] [Related]
8. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
[TBL] [Abstract][Full Text] [Related]
9. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
Dunford JE
Curr Pharm Des; 2010; 16(27):2961-9. PubMed ID: 20722615
[TBL] [Abstract][Full Text] [Related]
10. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Vorotnjak M; Boos J; Lanvers-Kaminsky C
Anticancer Drugs; 2004 Sep; 15(8):795-802. PubMed ID: 15494642
[TBL] [Abstract][Full Text] [Related]
11. Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2.
Koch FP; Merkel C; Al-Nawas B; Smeets R; Ziebart T; Walter C; Wagner W
J Craniomaxillofac Surg; 2011 Dec; 39(8):562-9. PubMed ID: 21030265
[TBL] [Abstract][Full Text] [Related]
12. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
Thompson K; Dunford JE; Ebetino FH; Rogers MJ
Biochem Biophys Res Commun; 2002 Jan; 290(2):869-73. PubMed ID: 11785983
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in understanding the mechanism of action of bisphosphonates.
Coxon FP; Thompson K; Rogers MJ
Curr Opin Pharmacol; 2006 Jun; 6(3):307-12. PubMed ID: 16650801
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth.
Mönkkönen H; Kuokkanen J; Holen I; Evans A; Lefley DV; Jauhiainen M; Auriola S; Mönkkönen J
Anticancer Drugs; 2008 Apr; 19(4):391-9. PubMed ID: 18454049
[TBL] [Abstract][Full Text] [Related]
15. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.
Thompson K; Rogers MJ
J Bone Miner Res; 2004 Feb; 19(2):278-88. PubMed ID: 14969398
[TBL] [Abstract][Full Text] [Related]
16. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
van beek E; Löwik C; van der Pluijm G; Papapoulos S
J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
18. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.
Wiemer AJ; Tong H; Swanson KM; Hohl RJ
Biochem Biophys Res Commun; 2007 Feb; 353(4):921-5. PubMed ID: 17208200
[TBL] [Abstract][Full Text] [Related]
19. Application of metabonomics in a comparative profiling study reveals N-acetylfelinine excretion as a biomarker for inhibition of the farnesyl pathway by bisphosphonates.
Dieterle F; Schlotterbeck G; Binder M; Ross A; Suter L; Senn H
Chem Res Toxicol; 2007 Sep; 20(9):1291-9. PubMed ID: 17676813
[TBL] [Abstract][Full Text] [Related]
20. New insights into the molecular mechanisms of action of bisphosphonates.
Rogers MJ
Curr Pharm Des; 2003; 9(32):2643-58. PubMed ID: 14529538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
